Modified immune cells for leukemia or lymphoma that has returned
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial tests a new type of CAR T-cell therapy that targets a protein called BAFF-R on your cancer cells. It is for people with B-cell ALL or lymphoma that has not responded to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- Your cancer must show a protein called BAFF-R on its cells.
- You must have tried or be unable to receive standard CAR T-cell therapy.
- If you had CAR T cells before, at least 3 months must have passed, and those cells must be below a certain level.
- Your heart, liver, kidney, and lung functions must be within acceptable ranges.
- You must not have certain infections like HIV, hepatitis B, or hepatitis C.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests a new type of immune-cell therapy (CAR T cells) that targets BAFF-R to treat certain relapsed or refractory B-cell non-Hodgkin lymphoma (NHL). It aims to see if the treatment is safe and can shrink lymphoma in people who have tried prior therapies.
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called BAFFR on B-cell blood cancers. The goal is to see if it can shrink tumors when given after a short chemotherapy course to prepare the body.
This trial tests a new type of immunotherapy called BAFF-R CAR-T cells for people with B-cell lymphoma that has come back or not responded to treatment, and whose cancer cells do not have the CD19 protein. The treatment uses your own immune cells, modified to target and kill the lymphoma cells.
This trial tests a new type of immunotherapy called CAR-T cell therapy that targets a protein (CD19) on cancer cells. It is for people with B-cell leukemia or lymphoma that has not responded to standard treatment or has come back, and the goal is to help their immune system fight the cancer.
This trial tests a new treatment called BAFF CAR-T cells for people with certain types of lymphoma or multiple myeloma that have come back or not responded to standard treatments. The treatment uses your own immune cells, modified in the lab to find and attack cancer cells, and is given as an infusion. The goal is to see if this can help control the disease when other options haven't worked.
This trial tests a new CAR-T cell treatment that targets a protein called BAFFR on cancer cells. It is for people with B-cell lymphoma that has come back or not responded to previous treatments.
Hear when a new Recurrent B Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.